HelioLiver LDT now available to order through Quest Diagnostics
Modern corporate skyline
Helio Genomics · Newsroom

Investor Relations

Recent press coverage and publications have highlighted Helio Genomics' market momentum in early cancer detection and diagnostics innovation.

Featured Coverage

Business Insider67.7M Monthly Visitors

Helio Genomics Announces New HelioLiver Access Through Quest

Business Insider covers the expanded provider access for HelioLiver beginning April 2026, detailing how healthcare providers with existing Quest accounts can order the blood-based liver cancer test through Quest's infrastructure of approximately 7,700 patient service centers and EHR integration.

Read the Coverage

In the Press

Helio Genomics' science, commercial milestones, and the Quest Diagnostics partnership have been covered across leading financial, industry, and clinical media.

Orange County Business Journal coverageNews
Orange County Business Journal61.2K UVM

Helio Genomics Enters Full Launch with Quest Diagnostics

Read on
Yahoo! News coverageNews
Yahoo! News44.5M UVM

Improving Early Detection and Treatment of Liver Cancer

Read on
FinanceWire coverageNews
FinanceWire102.2K UVM

Helio Genomics Announces New HelioLiver Access Through Quest

Read on
GlobalData coverageNews
GlobalData307.1K UVM

Improving Early Detection and Treatment of Liver Cancer

Read on
Dealroom.co coverageNews
Dealroom.co33K UVM

Quest Diagnostics to Offer Helio Genomics' AI-Powered Liver Cancer Blood Test Across US Network

Read on
Precision Medicine Online coverageNews
Precision Medicine Online156K UVM

Helio Genomics Mulls New AI-Driven Dx Opportunities While Readying Liver Cancer Test for US

Read on
Simply Wall St. News coverageNews
Simply Wall St. News2.5M UVM

How Investors May Respond to Quest Diagnostics (DGX) Expanding Blood-Based Cancer Screening and Boardroom Expertise

Read on
Scope Forward (Becker's GI & Endoscopy) coverageNews
Scope Forward (Becker's GI & Endoscopy)17.7K UVM

Quest Diagnostics to Offer Liver Cancer Blood Test

Read on
LiverRight coverageNews
LiverRight12.5K UVM

Helio Genomics and Quest Diagnostics

Read on
Becker's ASC Review coverageNews
Becker's ASC Review609K UVM

Quest Diagnostics to Offer Liver Cancer Blood Test

Read on
Brief Glance coverageNews
Brief Glance35K UVM

AI Blood Test for Liver Cancer Gains Massive Reach via Quest Deal

Read on
NewsBreak coverageNews
NewsBreak13.9M UVM

Quest Diagnostics to Offer Liver Cancer Blood Test

Read on
SAHM Capital coverageNews
SAHM Capital220.5K UVM

How Investors May Respond to Quest Diagnostics (DGX) Expanding Blood-Based Cancer Screening and Boardroom Expertise

Read on
Peer-Reviewed Science

Our Publications

For over a decade, Helio Genomics’ science has been published in the world’s most respected peer-reviewed journals — the research behind HelioLiver and the platform that powers it.

13+Years of published
science
9Peer-reviewed
publications
2Cancer indications
(HCC & CRC)
Molecular Cell2013

Genome-Wide Methylation Profiles Reveal Quantitative Views of Human Aging Rates

A large-scale clinical study on cfDNA methylation in relation to aging and age-related diseases, where Helio’s science began.

Open Publication pubmed.ncbi.nlm.nih.gov
Proceedings of the National Academy of Sciences (PNAS)2017

DNA Methylation Markers for Diagnosis and Prognosis of Common Cancers

A large-scale clinical study across liver, colon, lung, and breast cancers, validating new DNA methylation markers.

Open Publication pnas.org
Nature Materials2017

Circulating Tumour DNA Methylation Markers for Diagnosis and Prognosis of Hepatocellular Carcinoma

A large-scale clinical study of cfDNA methylation markers in the detection of HCC.

Open Publication nature.com
Science Translational Medicine2020

Circulating Tumor DNA Methylation Profiles Enable Early Diagnosis, Prognosis Prediction, and Screening for Colorectal Cancer

A large-scale clinical study of cfDNA methylation markers in the detection of colorectal cancer (CRC).

Open Publication science.org
Nature Communications2021

Cellular Heterogeneity–Adjusted cLonal Methylation (CHALM) Improves Prediction of Gene Expression

An advanced bioinformatics algorithm that strengthens how methylation data predicts gene expression, part of the science behind Helio’s platform.

Open Publication nature.com
Hepatology Communications2022

A Multi-Analyte Cell-Free DNA–Based Blood Test for Early Detection of Hepatocellular Carcinoma

The ENCORE study. Clinical validation of the HelioLiver product for early HCC detection.

Open Publication pubmed.ncbi.nlm.nih.gov
Journal of HepatologyLatest · 2026

A Multi-Analyte cfDNA-Based Blood Test for Early Detection of Hepatocellular Carcinoma

The pivotal CLiMB trial. HelioLiver detected liver cancer earlier than ultrasound in a large, prospective US study of high-risk patients.

Open Publication journal-of-hepatology.eu
Molecular Cancer2023

Efficacy of a Cell-Free DNA Methylation-Based Blood Test for Colorectal Cancer Screening in a High-Risk Population: A Prospective Cohort Study

Clinical validation of the colorectal cancer screening test in a high-risk population.

Open Publication molecular-cancer.biomedcentral.com
Genome Medicine2024

Multimodal Epigenetic Sequencing Analysis (MESA) of Cell-Free DNA for Non-Invasive Colorectal Cancer Detection

A multimodal sequencing approach for non-invasive colorectal cancer detection.

Open Publication genomemedicine.biomedcentral.com
View All Publications